---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-315196"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:31:02.312750+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline

## Summary
- Richard Fair appointed President, CEO and board member, effective December 11, 2025.
- Co-founder Sam Kintz transitions to Head of Pipeline, remains at Enliven.
- Fair receives $660,000 base salary, 55% target bonus, and option award for 875,000 shares.
- Kintz receives $500,000 base salary, 55% bonus, and acceleration of 140,457 stock options.
- Company plans to initiate Phase 3 trial for ELVN-001 in CML in 2026, citing need for commercialization expertise.

## SEC filing metadata
- accession: 0001193125-25-315196
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312525315196/0001193125-25-315196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312525315196/d937094d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-315196
- JSON: https://secwatch.observer/filing/0001193125-25-315196.json
- Plain text: https://secwatch.observer/filing/0001193125-25-315196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.